Last reviewed · How we verify
Travatan
At a glance
| Generic name | Travatan |
|---|---|
| Sponsor | Alcon Research |
| Target | Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Ocular hypertension
- Open-angle glaucoma
Common side effects
- Conjunctival hyperemia
- Ocular hyperemia
- Decreased visual acuity
- Eye discomfort
- Foreign body sensation
- Pain
- Pruritus
- Abnormal vision
- Blepharitis
- Blurred vision
- Cataract
- Conjunctivitis
Serious adverse events
- Angina pectoris
- Chest pain
- Arrhythmia
- Vomiting
- Epistaxis
- Tachycardia
- Bradycardia
- Hypotension
- Hypertension
- Insomnia
Key clinical trials
- Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE3)
- Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant (PHASE2, PHASE3)
- Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
- Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone (PHASE4)
- Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone (PHASE3)
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma (PHASE4)
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Travatan CI brief — competitive landscape report
- Travatan updates RSS · CI watch RSS
- Alcon Research portfolio CI